Description
Combating acquired resistance to EGFR tyrosine kinase inhibitors in lung cancer
Article: Combating acquired resistance to EGFR tyrosine kinase inhibitors in lung cancer
€3.03
Related products
-
Article: Updated results of the phase III COLUMBUS trial further solidify BRAF/MEK combinations as standard of care for BRAF-mutated advanced melanoma
€3.03 Add to cart -
Article: Highlights in gynaecological cancers
€3.03 Add to cart -
Article: Highlights in genitourinary cancers
€3.03 Add to cart -
Article: Highlights in urologic cancer
€3.03 Add to cart
